We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+55.06%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.8B
AUM Growth
+$694M
(+33%)
Cap. Flow
+$99M
Cap. Flow
% of AUM
3.54%
Top 10 Holdings %
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
25
Closed
5
Top Buys
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$63.5M |
| 2 |
Immunome
IMNM
|
+$32.3M |
| 3 |
Biohaven
BHVN
|
+$28.8M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$27.9M |
| 5 |
Abbott
ABT
|
+$26.5M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
+$30M |
| 2 |
Humana
HUM
|
+$29.1M |
| 3 |
Elevance Health
ELV
|
+$28.8M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$24M |
| 5 |
DexCom
DXCM
|
+$22.8M |
Sector Composition
| 1 | Healthcare | 94.12% |
| 2 | Industrials | 3.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $487M | 17.42% |
16,423,922
-1,079,495
| -6% | -$21.5M |
|
|
2
Krystal Biotech
KRYS
$10.2B
| $215M | 7.69% |
1,733,189
-270,178
| -13% | -$30M |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $210M | 7.53% |
14,828,321
-2,116,300
| -12% | -$24M |
|
4
Scholar Rock
SRRK
$6.46B
| $120M | 4.31% |
6,402,505
+1,669,257
| +35% | +$20.8M |
|
|
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $115M | 4.13% |
1,857,706
| – | – |
|
|
AUGX
6
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $95.8M | 3.43% |
16,380,327
+750,000
| +5% | +$3.95M |
|
|
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $77.4M | 2.77% |
4,801,540
+326,156
| +7% | +$4.16M |
|
|
8
State Street SPDR S&P 500 ETF Trust
SPY
$786B
| $67.7M | 2.42% |
+142,500
| New | +$63.5M |
|
9
Regenxbio
RGNX
$631M
| $67.5M | 2.41% |
3,760,690
+1,186,648
| +46% | +$20.9M |
|
|
10
Biohaven
BHVN
$2.23B
| $61.8M | 2.21% |
1,444,365
+925,441
| +178% | +$28.8M |
|
11
Zymeworks
ZYME
$1.81B
| $60.2M | 2.15% |
5,790,230
+129,000
| +2% | +$1.03M |
|
12
LivaNova
LIVN
$4.4B
| $58.8M | 2.1% |
1,137,068
+36,576
| +3% | +$1.77M |
|
13
ALX Oncology
ALXO
$272M
| $54.5M | 1.95% |
3,659,264
+2,375,975
| +185% | +$22.5M |
|
|
CTLT
14
DELISTED
CATALENT, INC.
CTLT
| $49.4M | 1.77% |
1,100,466
+226,500
| +26% | +$9.16M |
|
15
Fate Therapeutics
FATE
$346M
| $49.3M | 1.76% |
13,169,057
+44,630
| +0.3% | +$105K |
|
16
Pliant Therapeutics
PLRX
$68.7M
| $48.8M | 1.75% |
2,696,648
+18,549
| +0.7% | +$282K |
|
17
Kymera Therapeutics
KYMR
$9.31B
| $46.4M | 1.66% |
1,823,956
-44,551
| -2% | -$797K |
|
|
18
Immunome
IMNM
$2.58B
| $41.5M | 1.48% |
+3,879,415
| New | +$32.3M |
|
19
Immunovant
IMVT
$8.1B
| $41.2M | 1.47% |
977,072
-125,442
| -11% | -$4.62M |
|
20
Boston Scientific
BSX
$64.3B
| $40.1M | 1.43% |
693,200
-81,000
| -10% | -$4.32M |
|
21
Shattuck Labs
STTK
$607M
| $40.1M | 1.43% |
5,619,914
| – | – |
|
22
Celldex Therapeutics
CLDX
$3.02B
| $39.4M | 1.41% |
993,803
-642,135
| -39% | -$18.9M |
|
23
Beam Therapeutics
BEAM
$3.19B
| $38.9M | 1.39% |
1,429,783
-39,942
| -3% | -$992K |
|
24
Absci
ABSI
$1.67B
| $33.7M | 1.21% |
8,031,094
| – | – |
|
25
Nurix Therapeutics
NRIX
$2.46B
| $33.6M | 1.2% |
3,256,519
+407,692
| +14% | +$2.79M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO